Previous 10 | Next 10 |
Heron Therapeutics ( HRTX -0.1% ) announces the publication of results, online in the Journal of Arthroplasty , from a Phase 2b clinical trial, Study 209 , evaluating HTX-011 for postoperative pain relief in patients who have undergone total knee arthroplasty (knee replacement). More...
SAN DIEGO , June 4, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that...
SAN DIEGO , May 18, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced...
The COVID-19 pandemic has wrecked havoc on several major industries this year. However, the healthcare sector has been one of the few bright spots in this rather ugly market. A wide swath of the healthcare space, in fact, is in positive territory for the year right now. Generally speaking...
Heron Therapeutics (NASDAQ: HRTX ): Q1 GAAP EPS of -$0.57 beats by $0.08 . More news on: Heron Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
SAN DIEGO , May 6, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial ...
SAN DIEGO , April 9, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced tha...
Most major U.S. stock indices have rebounded sharply since hitting a multiyear low on March 23, 2020. The Dow Jones Industrial Average has gained a healthy 26% over the last two and a half weeks, while the S&P 500 has risen by nearly 23% during the same period. Despite this remarkable tu...
The FDA has accepted for review a marketing application from privately held Innocoll Holdings Limited seeking approval of Xaracoll (bupivacaine hydrochloride collagen-matrix implants) for the management of postsurgical pain after inguinal (groin) hernia surgery. The agency's action date is...
News, Short Squeeze, Breakout and More Instantly...
Heron Therapeutics Inc. Company Name:
HRTX Stock Symbol:
NASDAQ Market:
Heron Therapeutics Inc. Website:
Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024 PR Newswire SAN DIEGO , July 30, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company...
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System PR Newswire SAN DIEGO , July 15, 2024 /PRNewswire/ -- Heron Therapeutics, Inc....
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire -The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024 ...